Table 3.
HR | 95% CI | p | ||
---|---|---|---|---|
Age | 1.00 | 0.98 | 1.02 | 0.821 |
Female | 0.96 | 0.57 | 1.59 | 0.876 |
History of CHD | 1.48 | 0.84 | 2.61 | 0.170 |
Smoking | 1.17 | 0.71 | 1.93 | 0.532 |
HTN | 0.72 | 0.45 | 1.15 | 0.170 |
DM | 1.16 | 0.59 | 2.30 | 0.657 |
Dyslipidemia | 1.95 | 1.20 | 3.17 | 0.007 |
eGFR | 1.00 | 0.95 | 1.00 | 0.320 |
Antiplatelet agents | ||||
No antiplatelet agent | reference | |||
Aspirin | 1.00 | 0.61 | 1.62 | 0.987 |
Clopidogrel | 0.62 | 0.15 | 2.60 | 0.516 |
Aspirin + clopidogrel | 2.15 | 1.13 | 4.07 | 0.019 |
Definite spasm | 1.47 | 0.95 | 2.29 | 0.085 |
Calcium Channel blocker | 0.96 | 0.46 | 2.00 | 0.906 |
HR, Hazard ratio; CI, confidence interval; CHD, coronary heart disease; HTN, hypertension; DM, diabetes mellitus; PCI, percutaneous coronary intervention.
*Primary outcome includes death, acute coronary syndrome, and arrhythmia.